Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Spyre Therapeutics, Inc.

NASDAQ: SYRE · Life Sciences · 6 alerts · CIK 1636282

Share price
$99.37Close, Nov 16
Market cap
$9.44B
Shares outstanding
94.97MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Spyre Therapeutics, Inc. filings on SEC EDGAR ↗

4:02 PM ET 8-K
Financial Results

Spyre Therapeutics Financial Results

Spyre Therapeutics reported third quarter 2026 financial results, highlighting a pro forma cash position of $1.5 billion following a $400 million public offering in October. The company achieved clinical proof-of-concept for its three IBD monotherapies and is advancing combination trials with data expected in Q3 2027.

Term
Q3 2026

“We are increasingly well-positioned to deliver on our ambition of elevating the standard of care across immunology. In IBD, our three compelling Phase 2 monotherapy readouts and a growing body of supportive clinical evidence strengthen our conviction that our combination products have the potential to transform the treatment paradigm.”

Cameron Turtle, DPhil, Chief Executive Officer of Spyre
4:01 PM ET 10-Q
Financial Results

Spyre Therapeutics Q3 2026 Results: Net Loss of $96.1M, Loss Widens

Spyre Therapeutics reported a significant increase in its financial position, with total current assets growing from $777.8 million at the end of 2025 to approximately $1.1 billion as of September 30, 2026, primarily driven by an increase in marketable securities. The company is advancing its clinical pipeline, including the SKYLINE and SKYLIGHT Phase 2 trials, while maintaining a large accelerated filer status.

Key figure
Net loss $96.1M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.